Wilmington, DE, United States of America

John A Schwartz


Average Co-Inventor Count = 2.2

ph-index = 4

Forward Citations = 132(Granted Patents)


Location History:

  • Wilmington, all, DE (US) (1991)
  • Wilmington, DE (US) (1990 - 1998)

Company Filing History:


Years Active: 1990-1998

Loading Chart...
6 patents (USPTO):Explore Patents

Title: The Innovations of John A Schwartz

Introduction

John A Schwartz is a notable inventor based in Wilmington, DE (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of peptide derivatives. With a total of six patents to his name, Schwartz has demonstrated a commitment to advancing medical science through his innovative work.

Latest Patents

Among his latest patents, Schwartz has developed peptide derivatives that are pharmaceutically useful trifluoromethyl ketone substituted di-, tri-, and tetra-peptide derivatives. These compounds are designed to act as inhibitors of human leukocyte elastase. Additionally, he has created aminoalcohol intermediates for peptide derivatives, which also focus on the same therapeutic applications. His work includes the formulation of pharmaceutical compositions containing these peptide derivatives, along with the processes and intermediates necessary for their manufacture.

Career Highlights

Throughout his career, Schwartz has worked with prominent companies such as Ici Americas, Inc. and Zeneca Limited. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in the pharmaceutical industry.

Collaborations

Some of his notable coworkers include Philip D Edwards and Mark M Stein. Their collaboration has likely fostered an environment of innovation and creativity, further enhancing the impact of their collective work.

Conclusion

John A Schwartz's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his importance as an inventor. His work continues to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…